---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-112002"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:26:20.066385+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics secures up to $1B financing from Blackstone with $350M at close

## Summary
- Initial $350M at close: $300M senior secured term loan (7.25%+SOFR, 7-yr) and $50M common stock at $45.65/share.
- Additional $150M delayed draw debt available for 18 months; potential $500M further financing for BD.
- Collateral includes Translarna, Emflaza, Upstaza, sepiapterin, and vatiquinone assets.
- Standstill restrictions on Blackstone; 90-day lock-up on stock; registration rights for resale.

## SEC filing metadata
- accession: 0001104659-22-112002
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/0001104659-22-112002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/tm2229086d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-112002
- JSON: https://secwatch.observer/filing/0001104659-22-112002.json
- Plain text: https://secwatch.observer/filing/0001104659-22-112002.txt

## Key facts
- Debt Financings
  PTC THERAPEUTICS, INC. incurred credit facility of up to $950.0 million with Blackstone at adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rat maturing seven years from the Closing Date.
  - Instrument: credit facility
  - Principal: up to $950.0 million
  - Counterparty: Blackstone
  - Rate: adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rat
  - Maturity: seven years from the Closing Date
  - Event: incurrence
  source text: Debt Facility On October 27, 2022 (the “Closing Date”), PTC Therapeutics, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing, to the extent that the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/0001104659-22-112002-index.htm
- Material Agreements
  PTC THERAPEUTICS, INC. entered into Stock Purchase Agreement with certain entities affiliated with the Lenders (the “Purchasers”) valued at approximately $50.0 million (effective 2022-10-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain entities affiliated with the Lenders (the “Purchasers”)
  - Value: approximately $50.0 million
  - Effective: 2022-10-27
  source text: the Company and certain entities affiliated with the Lenders (the “Purchasers”) also entered into a stock purchase agreement on the Closing Date (the “Stock Purchase Agreement”) for the sale and issuance of 1,095,290 shares of common stock (the “Shares”) to the Purchasers at a price of $45.65 per share, for an aggregate purchase price of approximately $50.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/0001104659-22-112002-index.htm
- Material Agreements
  PTC THERAPEUTICS, INC. entered into Credit Agreement with funds and other affiliated entities advised or managed by Blackstone Life Sciences Advisors L.L.C. and Blackstone Alternative Credit Advisors LP valued at up to $950.0 million (effective 2022-10-27).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: funds and other affiliated entities advised or managed by Blackstone Life Sciences Advisors L.L.C. and Blackstone Alternative Credit Advisors LP
  - Value: up to $950.0 million
  - Effective: 2022-10-27
  source text: On October 27, 2022 (the “Closing Date”), PTC Therapeutics, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/0001104659-22-112002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.